Related references
Note: Only part of the references are listed.Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis
Daniel M. Hartung et al.
NEUROLOGY (2020)
Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis
Pengxiang Li et al.
VALUE IN HEALTH (2020)
Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?
Juan Ignacio Rojas et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Medication adherence/persistence among patients with active multiple sclerosis in Finland
Sanni Lahdenpera et al.
ACTA NEUROLOGICA SCANDINAVICA (2020)
Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany
Sabrina Mueller et al.
NEUROLOGY AND THERAPY (2020)
MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis
Jose M. A. Wijnands et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Patients' preferences and willingness-to-pay for disease-modifying therapies
Natasha Frost et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Tomas Kalincik et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan
Lina H. Al-Sakran et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2018)
Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study
Jose Maria Andreas Wijnands et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis
Alexander Rae-Grant et al.
NEUROLOGY (2018)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis
Rishi J. Desai et al.
Journal of Managed Care & Specialty Pharmacy (2018)
Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?
Ricardo Alonso et al.
JOURNAL OF CLINICAL NEUROLOGY (2018)
Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study
Nils Koch-Henriksen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
Valery L. Feigin et al.
LANCET NEUROLOGY (2017)
A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis
Catherine Bottomley et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Ann Marie Weideman et al.
FRONTIERS IN NEUROLOGY (2017)
Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts
Nana Amankwah et al.
HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION IN CANADA-RESEARCH POLICY AND PRACTICE (2017)
Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis
Ana L. Hincapie et al.
Journal of Managed Care & Specialty Pharmacy (2017)
Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey
Hillary J. Gross et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2017)
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis
T. Spelman et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
The challenge of comorbidity in clinical trials for multiple sclerosis
Ruth Ann Marrie et al.
NEUROLOGY (2016)
Administrative health data in Canada: lessons from history
Kelsey Lucyk et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2015)
High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010)
Elaine Kingwell et al.
JOURNAL OF NEUROLOGY (2015)
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Alberto Gajofatto et al.
WORLD JOURNAL OF CLINICAL CASES (2015)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Management of Multiple Sclerosis During Pregnancy and the Reproductive Years A Systematic Review
Riley Bove et al.
OBSTETRICS AND GYNECOLOGY (2014)
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Kathrin S. Utz et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada
Ruth Ann Marrie et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2013)
Switching Therapies in Multiple Sclerosis
Patricia K. Coyle
CNS DRUGS (2013)
The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform
Vilija G. Jokubaitis et al.
PLOS ONE (2013)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries
Hude Quan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2011)
Administrative Record Linkage as a Tool for Public Health Research
Douglas P. Jutte et al.
ANNUAL REVIEW OF PUBLIC HEALTH, VOL 32 (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
The rising prevalence and changing age distribution of multiple sclerosis in Manitoba
R. A. Marrie et al.
NEUROLOGY (2010)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Parkinson's disease, multiple sclerosis and changes of residence in Alberta
Nikolaos Yiannakoulias et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2007)
Share Paper
